Light Adjustable Lens (LAL) for Cataract Surgery — What Patients Should Know

The Light Adjustable Lens (LAL) is a genuinely novel technology in intraocular lens design. Unlike all other IOLs, which have a fixed refractive power once implanted, the LAL can be fine-tuned after surgery using a series of brief UV light treatments in the surgeon's office. This post-implantation adjustability is the lens's defining and differentiating feature.

This article reviews what the LAL is, what the current evidence shows about its benefits and limitations, who may genuinely benefit from it, and what patients should understand before weighing it as an option. The goal is not to promote or dismiss the technology — it is to present the evidence clearly so that you can have an informed conversation with your surgeon.

How the Light Adjustable Lens Works

The LAL (manufactured by RxSight) is made from a photosensitive silicone material containing special macromers (light-reactive molecules) distributed throughout the lens. After standard cataract surgery implantation, the lens behaves like any other IOL. However, over the following weeks, before the final lens power is "locked in," the surgeon can perform a series of targeted UV light delivery treatments using a specialised device.

Each UV treatment causes the photosensitive macromers in the targeted area of the lens to polymerise (solidify), changing the local curvature of the lens and thereby adjusting its refractive power. By selectively treating different zones, the surgeon can increase or decrease the overall power, correct residual astigmatism, or add multifocal characteristics. Once the desired refraction is achieved and confirmed — typically after 3 to 5 treatment sessions over several weeks — a final "lock-in" treatment permanently stabilises the lens.

The Theoretical Advantage

The fundamental problem the LAL addresses is the inherent imprecision of pre-operative IOL power calculation. Even with the most sophisticated modern biometry equipment, predicting with perfect accuracy what lens power will produce 20/20 vision in a given eye involves estimation. The cornea's healing response after surgery, variations in effective lens position, and the inherent limits of measurement all contribute to a residual refractive error in some patients — meaning they need glasses for reasons unrelated to the quality of their surgery.

For most patients, this residual error is small and easily corrected with glasses or contact lenses. For patients who strongly prioritise spectacle independence, however, even a small refractive surprise can be frustrating. The LAL's post-operative adjustability offers a way to correct this residual error before the lens is permanently locked.

This advantage is particularly compelling for a specific subset of patients: those with a history of prior corneal refractive surgery (LASIK, PRK, or radial keratotomy). In these patients, standard biometric formulas are known to be less accurate because prior laser treatment has changed the corneal curvature in ways that affect the refractive index measurements used to calculate IOL power. The ability to fine-tune post-operatively may meaningfully improve outcomes for this group.

What the Evidence Currently Shows

FDA Pivotal Trial Data

The LAL received FDA approval in the United States in 2017, based on a pivotal clinical trial. Published data from this and subsequent studies (Hovanesian et al., Journal of Cataract and Refractive Surgery, 2020) showed that a greater proportion of LAL patients achieved uncorrected distance visual acuity of 20/20 or better compared to a standard IOL control group — a positive finding in favour of the LAL for refractive precision outcomes.

These are meaningful results. However, the pivotal trial was sponsored by the manufacturer, and interpreting industry-sponsored pivotal trials requires the same careful reading applied to any single source. The trial design and outcome selection may not fully capture all clinically relevant considerations, and the comparison group (standard monofocal IOL) was not a toric IOL, which is the more appropriate comparator for a refractive precision-focused lens.

Independent Evidence Landscape

As of 2025, no independent Cochrane-level systematic review of the LAL has been published. Emerging real-world data and independent case series are generally positive for refractive precision outcomes in appropriate candidates. Studies examining LAL outcomes in post-LASIK patients report promising results — which aligns with the theoretical rationale for its use in this group.

What is more limited is the long-term evidence. The standard monofocal IOL has safety and efficacy data spanning 30 to 40 years of widespread clinical use. The LAL's evidence base, while growing, represents a far shorter follow-up period. This is not a reason to avoid the technology — all new technologies start with shorter follow-up — but it is context that a well-informed patient should have.

Who May Genuinely Benefit

Based on current evidence and clinical reasoning, the LAL may be most appropriate for:

• Post-refractive surgery patients: Those with a history of LASIK, PRK, LASEK, or radial keratotomy, where standard IOL power calculations carry greater uncertainty. The ability to fine-tune post-operatively may substantially reduce the risk of a refractive surprise.
• Patients with high refractive error: Those with high degrees of myopia or hyperopia, where small errors in biometry can translate into larger refractive outcomes.
• Patients who strongly prioritise refractive precision: Those for whom achieving a specific refractive target (e.g., precise plano or a specific monovision target) is a high priority and who understand and accept the post-operative treatment process and UV compliance requirements.

Who May Not Need the LAL

The average patient presenting with a straightforward age-related cataract and a normal, previously untreated cornea already achieves excellent refractive outcomes with standard or toric IOLs. Modern biometric platforms routinely achieve within 0.5 dioptre of the target refraction in the majority of patients in experienced hands. For these patients, the incremental precision advantage of the LAL — and its associated additional cost, compliance burden, and shorter evidence track record — may not represent a net benefit.

Patients with poor compliance ability (for UV glasses), limited access to multiple post-operative treatment visits, or expectations that the LAL will eliminate all need for glasses in all conditions should also discuss these factors frankly with their surgeon before choosing this lens.

Cost and Compliance Considerations

The LAL carries a significant cost premium above the MSP-covered standard IOL — the precise fee will be quoted by your surgeon's office and varies by centre. This cost should be weighed against the clinical benefit relative to your individual candidacy.

The compliance requirement — UV-protective glasses worn at all times outdoors until the lock-in treatment — is non-negotiable. Failure to comply can result in unplanned lens changes that are difficult to correct. Multiple office visits over several weeks are also required, which may be inconvenient for patients with limited mobility or who live at a distance from the surgical centre.